RE:RE:RE:RE:Silence Well another week and continued silence from Management.
Was CATCO study positive?? Unknown. Study was approved I believe in February. When was the final dosing completed? Are the final results in? Has a independent peer review commenced?
Covid 19, RSV are surging around the world, lung inflammation is a concern.
Yes I know kidney inflammation might be their sweet spot but sometimes you need to strike when the iron is hot.
If Kidney is their next study, when? How are they funding? Do they plan to raise capital when share price at $3, hopefully not.
I am beyond frustrated with the lack of communication.
Cb27743 wrote: River,
What I am referrring to is not creating fluff news from management, but being transparent to the public regarding the current trial (if they can) and completed P2 trial. There must of been atleast 1 material update in the 9 month duration management could of shared to the public regarding the drug status. We understand CATCO is a 3rd party trial with the assistance from Arch, but providing 1 public drug update since February is unnacceptable from an investor viewpoint and others have shared their frustration on other platforms. We are not questioning the companies ability to commercialization, we are feeling pretty confident with the team and their credentials, we just want Arch management to be more open with news to the Market. IMO Arch had multiple share price, market cap opportunities to get off this junior party aka the Venture exchange which would of really exposed more interest, even if they just upgraded to the TO exhange where reputable funds want to establish their investments, but they stayed in ghost mode as per their normal and now it is Round 14 for losers who missed to the boat to buy back in at $2.80-$3.20 and a rare good volume day. Arch will most likely be cheaper in the near future if management continues to stay quiet and if someone decides to liquidate their shares during tax loss season approaching.
Just my thoughts River